Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPain ManagementAetna Laser Neurolysis Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentAetnaPolicy 0552

    Laser Neurolysis

    Customize your policy alerts

    Sign up for Aetna Policy 0552 alerts

    Get alerted when Policy 0552 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Aetna's coverage stance on laser neurolysis (noninvasive laser application to peripheral nerves) for treatment of pain-related indications and lists indications considered experimental/investigational. It applies to Aetna plan providers and members.

    Policy Summary
    PayerAetna
    PolicyLaser Neurolysis
    Policy CodePolicy 0552
    Change TypeNo material change
    Effective DateAug 14, 2001
    Last ReviewJul 27, 2023
    Next Review DateJun 13, 2024
    Key ActionDo not expect prior authorization approval for laser peripheral nerve block for indications listed as experimental and investigational.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5experimental indications
    0552policy #
    1997-2023study years
    07/27/2023last review

    Coverage Criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Experimental and Investigational — Not covered

    Not covered (considered experimental and investigational) for the following indications due to insufficient evidence of effectiveness:

    Experimental/Investigational Indications: Carpal tunnel syndrome; Complex regional pain syndrome; Facet joint pain; Phantom limb pain; Sacroiliac joint pain.

    List is not all-inclusive per policy.

    The ICD-10 codes listed in this policy are not covered when billed for the indications specified in this Clinical Policy Bulletin. This list is not all-inclusive; claims using the ICD-10 codes below for the investigational indications described in the policy are subject to denial or prior authorization failure.

    Coding

    Codes mentioned in policy (ICD-10 and related CPT ranges)mixed
    64600-64610Destruction by neurolytic agent, trigeminal nerve
    64620-64640Destruction by neurolytic agent, intercostal nerve, paravertebral facet joint nerve, or pudendal nerve
    64702-64704Neuroplasty, digital, one or both, same digit or nerve of hand or foot
    64708-64714Neuroplasty, major peripheral nerve, arm or leg, open
    64727Internal neurolysis, requiring the use of operating microscope (List separately in addition to code for neuroplasty)
    G54.6Phantom limb syndrome with pain
    G56.00-G56.03Carpal tunnel syndrome
    G56.40-G56.42Causalgia of upper limb (CRPS II of upper limb)
    G57.70-G57.73Causalgia of lower limb (CRPS II of lower limb)
    G90.50-G90.59Complex regional pain syndrome I (CRPS I)
    1–10 of 16
    1/2

    Provider Actions and Billing Notes

    Prior Authorization

    Prior authorization expectation — unlikely to approve

    Aetna considers laser peripheral nerve block (laser neurolysis) experimental and investigational for specified indications and therefore it would not meet medical necessity; prior authorization approvals are unlikely for these indications.

    Step Therapy

    Conservative therapy preference for CRPS

    For complex regional pain syndrome (CRPS), the literature emphasizes physiotherapy-based interventions (e.g., graded motor imagery, mirror therapy) over laser neurolysis; conservative modalities are preferred given the low or very low quality evidence for most interventions and only small, short-term effects reported for laser therapy.

    Documentation Required

    Supporting clinical documentation required

    Include diagnosis and supporting diagnostic testing/results when claiming benefit from laser neurolysis; studies of carpal tunnel specified objective nerve conduction parameters for participant selection.

    • Document clinical diagnosis (e.g., carpal tunnel syndrome) and relevant diagnostic testing.
    • Include nerve conduction study results such as CMAP distal latency and sensory nerve action potential values reported in the carpal tunnel study.
    Denial Risk

    Denial risk for experimental/investigational indications

    Claims for laser peripheral nerve block (laser neurolysis) for indications listed as experimental and investigational (for example, carpal tunnel syndrome, CRPS, facet joint pain, phantom limb pain, sacroiliac joint pain) are subject to denial due to insufficient evidence of effectiveness.

    Background

    Laser neurolysis is the non‑invasive application of laser to peripheral nerves and is considered a form of low‑level laser therapy. It has been investigated primarily in small, uncontrolled studies for conditions such as carpal tunnel syndrome and facet joint pain, but available evidence is limited by small sample sizes, short follow‑up, and lack of control groups.

    Definitions

    Laser neurolysis definition
    DefinitionLaser neurolysis is the non‑invasive application of laser to peripheral nerves; it is considered a form of low‑level laser therapy.
    Primary investigational indicationPrimarily investigated for treatment of carpal tunnel syndrome in small, uncontrolled studies (e.g., Weintraub 1997).
    Typical treatment parameters reportedExample study delivered 15 treatments using a gallium aluminum arsenide infrared continuous laser (830 nm wavelength, 30 mW output), 9 Joules per point at 5 points along the median nerve.
    Reported objective selection criteria in studiesParticipants had pre‑treatment compound muscle action potential distal latency >4.0 ms and sensory nerve action potential >3.7 ms.
    Reported outcomes and study limitationsOne series reported 77% complete symptom resolution but noted limitations including small size, short duration, and lack of a control group.

    Conservative Treatment Requirements

    Imaging and Diagnostic Requirements

    Note

    Carpal tunnel study nerve conduction parameters

    In the carpal tunnel study, investigators selected participants using objective nerve conduction parameters such as compound muscle action potential distal latency >4.0 ms and sensory nerve action potential >3.7 ms; include these reported measures when documenting cases similar to the study population.

    • CMAP distal latency greater than 4.0 milliseconds.
    • Sensory nerve action potential greater than 3.7 milliseconds.

    Not Covered / Exclusions

    The following indications are not covered (considered experimental and investigational) due to insufficient evidence of effectiveness: carpal tunnel syndrome; complex regional pain syndrome (CRPS I and II); facet joint pain; phantom limb pain; and sacroiliac joint pain. Corresponding ICD‑10 codes listed in the policy (for example, G56.00–G56.03 for carpal tunnel syndrome; G90.50–G90.59 and G56.40–G56.42 for CRPS; G54.6 for phantom limb pain; M53.3 for sacroiliac joint pain) are not covered when used for these indications.

    Policy Summary
    PayerAetna
    PolicyLaser Neurolysis
    Policy CodePolicy 0552
    Change TypeNo material change
    Effective DateAug 14, 2001
    Last ReviewJul 27, 2023
    Next Review DateJun 13, 2024
    Key ActionDo not expect prior authorization approval for laser peripheral nerve block for indications listed as experimental and investigational.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions and Billing NotesBackgroundDefinitionsConservative Treatment RequirementsImaging and Diagnostic RequirementsNot Covered / Exclusions